About
I am a biological engineer aiming to build technologies and processes to accelerate…
Activity
-
After 10 years of working on novel battery materials and process scale-up, I’m excited to share that I have joined Tesla’s In-house Cell team as Sr…
After 10 years of working on novel battery materials and process scale-up, I’m excited to share that I have joined Tesla’s In-house Cell team as Sr…
Liked by Brian Belmont
-
My deep thanks to the awards committee for selecting me as an honoree for the 40 under 40 Emerging Leaders in Cancer Award. This is a wonderful honor…
My deep thanks to the awards committee for selecting me as an honoree for the 40 under 40 Emerging Leaders in Cancer Award. This is a wonderful honor…
Liked by Brian Belmont
Experience
Education
-
Massachusetts Institute of Technology
-
Activities and Societies: SynBERC East Coast Synthetic Biology Working Group (Coordinator), International Genetically Engineered Machines (iGEM) mentor, Dept. of Biological Engineering student board, elective courses within the Sloan School of Business
-
-
Activities and Societies: Stanford Solar Car Project, elective courses within the School of Engineering
Publications
-
Engineering a direct and inducible protein-RNA interaction to regulate RNA biology
ACS Chemical Biology
-
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
Cancer Chemotherapy and Pharmacology
Patents
-
Single cell characterization using affinity-oligonucleotide conjugates and vessel barcoded polynucleotides
Issued US11156611B2
Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates. In some aspects, such methods may comprise attaching a first vessel barcoded polynucleotide to an oligonucleotide portion of an affinity-oligonucleotide conjugate, which binds to a target antigen expressed by a single cell that is isolated in a single vessel. In some aspects, the oligonucleotide portion of the affinity-oligonucleotide conjugate may comprise an antigen…
Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates. In some aspects, such methods may comprise attaching a first vessel barcoded polynucleotide to an oligonucleotide portion of an affinity-oligonucleotide conjugate, which binds to a target antigen expressed by a single cell that is isolated in a single vessel. In some aspects, the oligonucleotide portion of the affinity-oligonucleotide conjugate may comprise an antigen identification sequence (AID). In some aspects, the oligonucleotide portion of the affinity-oligonucleotide conjugate may further comprise an affinity molecular barcode (AMB) sequence. In some aspects, such methods may further comprise lysing the single cell and attaching a second vessel barcoded polynucleotide to a cell polynucleotide from the single cell.
Other inventorsSee patent -
Affinity-oligonucleotide conjugates and uses thereof
Issued US11061030B2
Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates. Provided herein are methods and compositions for single cell charaterization using tetramer-oligonucleotide conjugates.
Other inventorsSee patent -
High throughput process for t cell receptor target identification of natively-paired t cell receptor sequences
Issued 10,928,392
Provided herein are methods and composition for high-throughput T-cell receptor target identification of natively paired T-cell receptor sequences.
Other inventorsSee patent -
Methods of selecting T cell receptors using affinity oligonucleotide conjugates
Issued US 10,393,743
Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates, including tetramer-oligonucleotide conjugates (e.g., pMHC-oligonucleotide). In some aspects, such methods may comprise the steps of: forming a vessel comprising an affinity-oligonucleotide conjugate and a T cell; attaching a vessel barcoded polynucleotide or complement thereof to: (a) an oligonucleotide portion of a pMHC-oligonucleotide conjugate, and (b) a T cell receptor…
Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates, including tetramer-oligonucleotide conjugates (e.g., pMHC-oligonucleotide). In some aspects, such methods may comprise the steps of: forming a vessel comprising an affinity-oligonucleotide conjugate and a T cell; attaching a vessel barcoded polynucleotide or complement thereof to: (a) an oligonucleotide portion of a pMHC-oligonucleotide conjugate, and (b) a T cell receptor (TCR) polynucleotide originating from the T cell; and sequencing the oligonucleotide portion or a complement thereof and the TCR polynucleotide or a complement thereof. Additional methods provided herein include determining the binding affinity of a T cell receptor (TCR) to a pMHC-oligonucleotide. Compositions of the present invention encompass a plurality of vessels, wherein a vessel of the plurality of vessels may comprise a single T cell; and a vessel barcoded polynucleotide, wherein the vessel may further comprise a pMHC-oligonucleotide conjugate.
Other inventorsSee patent -
HPV-SPECIFIC BINDING MOLECULES
Filed US WO/2019/070541
Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
Other inventorsSee patent -
SINGLE AMPLICON ACTIVATED EXCLUSION PCR
Filed US WO/2017/053903
Provided herein are methods and compositions for activated amplification of a single template polynucleotide molecule, such as for cell barcoding and DNA sequencing.
Other inventorsSee patent -
Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
Issued US 9125931
In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a…
In vitro SELEX has been used to discover high affinity RNA aptamers interacting with the tetracycline repressor protein in a tetracycline-dependent manner. Using in silico RNA folding predictions to guide the design of both aptamer truncations and mutants, minimized tetracycline repressor protein high affinity binding aptamers have been defined. Using one such aptamer, inducible post-transcriptional regulation in vivo has been demonstrated that is predicated on a direct interaction between a tetracycline repressor protein and a RNA aptamer element. These aptamer components can be integrated in any organism to inducibly regulate RNA translation of a gene of interest.
Other inventorsSee patent -
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
Filed WO2020160050A1
Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells…
Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1 -binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.
Honors & Awards
-
Momenta Presidential Graduate Fellow, MIT
MIT
More activity by Brian
-
We appreciate the recognition and snapshot from Nasdaq highlighting our $375M in funding led by Sutter Hill Ventures and T. Rowe Price. This funding…
We appreciate the recognition and snapshot from Nasdaq highlighting our $375M in funding led by Sutter Hill Ventures and T. Rowe Price. This funding…
Liked by Brian Belmont
-
🚨 Life update: I decided to leave Twingate in March, the company I founded with Lior Rozner and Tony Huie more than 5 years ago. This was the…
🚨 Life update: I decided to leave Twingate in March, the company I founded with Lior Rozner and Tony Huie more than 5 years ago. This was the…
Liked by Brian Belmont
-
Today is the first day of the last month in my current position. I feel so fortunate to have been involved in the most innovative, influential…
Today is the first day of the last month in my current position. I feel so fortunate to have been involved in the most innovative, influential…
Liked by Brian Belmont
-
Hi friends, I was recently let go from my position, and I'm on the search for something new and epic. I know times are tough right now across the…
Hi friends, I was recently let go from my position, and I'm on the search for something new and epic. I know times are tough right now across the…
Liked by Brian Belmont
-
What were the 50 most successful life sciences startups of the past 15 years? 🧬🚀 In this installment of our Pear VC Biotech: Bench to Business…
What were the 50 most successful life sciences startups of the past 15 years? 🧬🚀 In this installment of our Pear VC Biotech: Bench to Business…
Liked by Brian Belmont
-
Washington Research Foundation has awarded nearly $2.2 million in new grant funding to researchers at Fred Hutch, Seattle Hub for Synthetic Biology…
Washington Research Foundation has awarded nearly $2.2 million in new grant funding to researchers at Fred Hutch, Seattle Hub for Synthetic Biology…
Liked by Brian Belmont
-
I’m representing Fulcrum Genomics LLC at #ASGCT today and tomorrow - reach out and say hello if you’re there!
I’m representing Fulcrum Genomics LLC at #ASGCT today and tomorrow - reach out and say hello if you’re there!
Liked by Brian Belmont
-
Very excited to have this come out! https://lnkd.in/gbifPDY8
Very excited to have this come out! https://lnkd.in/gbifPDY8
Liked by Brian Belmont
-
Are you one of the many who has been impacted by biotech/pharma layoffs in Seattle? Are you looking for a supportive network of others who have been…
Are you one of the many who has been impacted by biotech/pharma layoffs in Seattle? Are you looking for a supportive network of others who have been…
Liked by Brian Belmont
-
Today is my last day of an incredible journey. I want to express my gratitude to the Celgene Pharma/Bristol Myers Squibb family for a great 9 year…
Today is my last day of an incredible journey. I want to express my gratitude to the Celgene Pharma/Bristol Myers Squibb family for a great 9 year…
Liked by Brian Belmont
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Brian Belmont in United States
-
Brian Belmont
-
Brian Belmont
-
Brian Belmont
-
Brian Belmont
Executive Principal at CONSTELLATION SCHOOLS: ELYRIA COMMUNITY, LORAIN COMMUNITY ELEMENTARY, LORAIN COMMUNITY MIDDLE
11 others named Brian Belmont in United States are on LinkedIn
See others named Brian Belmont